CTRX-101
Prevention of accidental fentanyl overdose in high-risk patients
PreclinicalActive
Key Facts
Indication
Prevention of accidental fentanyl overdose in high-risk patients
Phase
Preclinical
Status
Active
Company
About CounterX Therapeutics
CounterX Therapeutics is a preclinical-stage biotech tackling the opioid crisis with a dual-pronged approach of monoclonal antibodies and vaccines. Its lead candidate, CTRX-101, is a long-acting anti-fentanyl antibody designed to prevent accidental overdose, with an IND filing anticipated in Q2 2026. The company leverages its proprietary CounterXCL™ discovery platform, which integrates immunology, bioengineering, and AI, to develop targeted solutions for opioid dependence and overdose prevention.
View full company profile